Ema accepts filing of marketing authorization application for valneva's inactivated covid-19 vaccine candidate

Saint herblain (france), may 1 9 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today confirmed that the european medicines agency (“ema”) has accepted the filing of a marketing authorization application (maa) for valneva's inactivated, whole-virus covid-19 vaccine candidate, vla2001. acceptance of the maa means vla2001 is advancing from the rolling review process and beginning the formal review process by the ema's committee for human medicinal products (chmp). if the chmp accepts valneva's conditional marketing authorization application, the company confirms it would expect to receive a positive chmp opinion in june 2022.
VALN Ratings Summary
VALN Quant Ranking